發(fā)布時(shí)間：2018-09-12 15:48

【摘要】：背景:肺動(dòng)脈高壓(PAH)是一種嚴(yán)重的肺血管疾病。肺動(dòng)脈高壓的定義是指平均肺動(dòng)脈壓大于25mmHg。肺動(dòng)脈高壓的病理特征是遠(yuǎn)端肺動(dòng)脈內(nèi)膜增生、叢狀病變、肌肉梗死和血栓形成逐漸發(fā)展成腔的閉塞,肺動(dòng)脈壓持續(xù)增高并最終導(dǎo)致右心衰竭。以前的研究發(fā)現(xiàn)甲羥戊酸途徑在心血管重塑中起重要作用。然而,甲羥戊酸途徑是否參與肺動(dòng)脈高壓疾病的發(fā)生和發(fā)展仍然是未知。本研究旨在研究甲基戊酸途徑中的關(guān)鍵酶在野百合堿(MCT)誘導(dǎo)的肺動(dòng)脈高壓疾病模型中的表達(dá)是否發(fā)生了變化。方法:F344大鼠隨機(jī)分成兩組(每組6只):對(duì)照組按大鼠體重一次性腹腔注射生理鹽水;MCT誘導(dǎo)造模組按體重一次性腹腔注射MCT(60mg/kg)。正常喂養(yǎng)4周后,測(cè)量大鼠右心室收縮壓,收集大鼠肺動(dòng)脈和肺組織,檢測(cè)甲羥戊酸途徑中相關(guān)酶和下游因子在肺動(dòng)脈中的表達(dá)。結(jié)果:在本研究中,我們檢測(cè)到了包括FDPS、FNTA和GGTase-I在內(nèi)的甲羥戊酸途徑中關(guān)鍵酶的表達(dá)量在肺動(dòng)脈高壓中發(fā)生了顯著增加。同時(shí),小G蛋白R(shí)hoA和Racl的表達(dá)量也上調(diào)了,其下游因子ROS和NADPH的活性增加,eNOS和血清中NO的量下調(diào)。結(jié)論:在肺動(dòng)脈高壓中FDPS、FNTA和GGTase-I的表達(dá)量發(fā)生了變化,暗示著甲羥戊酸途徑參與了肺動(dòng)脈高壓的病理發(fā)展。這種機(jī)制可能是通過(guò)調(diào)節(jié)小G蛋白實(shí)現(xiàn)的。這些結(jié)果可能會(huì)為肺動(dòng)脈高壓的治療提供潛在的藥物作用靶點(diǎn)。
[Abstract]:Background: pulmonary hypertension (PAH) is a severe pulmonary vascular disease. Pulmonary hypertension is defined as the mean pulmonary artery pressure greater than 25 mm Hg. The pathological features of pulmonary hypertension are hyperplasia of the distal pulmonary artery intima, plexiform lesions, muscle infarction and thrombosis gradually develop into lumen occlusion, pulmonary artery pressure continues to increase and eventually lead to right heart failure. Previous studies have found that the mevalic acid pathway plays an important role in cardiovascular remodeling. However, whether mevalic acid pathway is involved in the development of pulmonary hypertension is still unknown. The purpose of this study was to investigate whether the expression of key enzymes in methylvalerate pathway has changed in the model of pulmonary hypertension induced by monocrotaline (MCT). Methods Twenty F344 rats were randomly divided into two groups (6 rats in each group): the control group (n = 6) was treated with intraperitoneal injection of MCT (60mg/kg). After 4 weeks of normal feeding, the systolic blood pressure of right ventricle was measured, pulmonary artery and lung tissues were collected, and the expression of related enzymes and downstream factors in pulmonary artery were detected. Results: in this study, we detected a significant increase in the expression of key enzymes in the mevallic acid pathway, including FDPS,FNTA and GGTase-I, in pulmonary hypertension. At the same time, the expression of small G protein RhoA and Racl was up-regulated, and the activities of ROS and NADPH, the downstream factors, increased the activity of Enos and down-regulated the amount of NO in serum. Conclusion: the expression of FDPS,FNTA and GGTase-I changes in pulmonary hypertension, suggesting that mevalerate pathway is involved in the pathological development of pulmonary hypertension. This mechanism may be achieved by regulating small G protein. These results may provide potential drug targets for the treatment of pulmonary hypertension.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R544.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 黃震華;肺動(dòng)脈高壓治療進(jìn)展[J];高原醫(yī)學(xué)雜志;2001年01期

2 袁志明;阻塞性睡眠呼吸暫停綜合征與肺動(dòng)脈高壓研究進(jìn)展[J];國(guó)外醫(yī)學(xué).呼吸系統(tǒng)分冊(cè);2002年03期

3 郭明好,牛文革,劉云,劉向東,許清玉,楊磊;激素加環(huán)磷酰胺沖擊治療原發(fā)性干燥綜合征合并肺動(dòng)脈高壓5例[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2003年14期

4 王虹,王祥;肺源性肺動(dòng)脈高壓研究進(jìn)展[J];江蘇醫(yī)藥;2004年09期

5 朱萍,倪松石;慢性阻塞性肺疾病并發(fā)肺動(dòng)脈高壓的治療進(jìn)展[J];中國(guó)交通醫(yī)學(xué)雜志;2004年04期

6 鄧長(zhǎng)金;混合性結(jié)締組織病致肺動(dòng)脈高壓1例[J];臨床心血管病雜志;2005年04期

7 錢(qián)衛(wèi)民;珠蛋白生成障礙性貧血合并肺動(dòng)脈高壓1例[J];嶺南心血管病雜志;2005年05期

8 彭翠萍;;混合性結(jié)締組織病合并肺動(dòng)脈高壓1例[J];罕少疾病雜志;2005年06期

9 劉超,劉剛,劉坤申;內(nèi)皮素受體拮抗劑與肺動(dòng)脈高壓的治療[J];中國(guó)實(shí)用內(nèi)科雜志;2005年01期

10 陸慰萱;;肺動(dòng)脈高壓的新分類(lèi)[J];中國(guó)實(shí)用內(nèi)科雜志;2006年01期

相關(guān)會(huì)議論文 前10條

1 沈敏;張p，

本文編號(hào)：2239494